BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Azuma T, Ito S, Suto H, Ito Y, Miyaji H, Yamazaki Y, Kato T, Kuriyama M. Pharmacokinetics of clarithromycin in Helicobacter pylori eradication therapy in patients with liver cirrhosis. Aliment Pharmacol Ther 2000;14 Suppl 1:216-22. [PMID: 10807427 DOI: 10.1046/j.1365-2036.2000.014s1216.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
Number Citing Articles
1 Jung SW, Lee SW, Hyun JJ, Kim DI, Koo JS, Yim HJ, Park JJ, Lee HS, Chun HJ, Um SH. Efficacy of Helicobacter pylori eradication therapy in chronic liver disease. Dig Liver Dis. 2009;41:134-140. [PMID: 18436489 DOI: 10.1016/j.dld.2008.03.005] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
2 Weersink RA, Bouma M, Burger DM, Drenth JPH, Harkes-Idzinga SF, Hunfeld NGM, Metselaar HJ, Monster-Simons MH, van Putten SAW, Taxis K, Borgsteede SD. Safe use of proton pump inhibitors in patients with cirrhosis. Br J Clin Pharmacol. 2018;84:1806-1820. [PMID: 29688583 DOI: 10.1111/bcp.13615] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
3 Sanchez-Mete L, Zullo A, Hassan C, Rinaldi V, Magno MS, Festuccia F, Morini S, Attili AF. Helicobacter pylori diagnosis in patients with liver cirrhosis. Dig Liver Dis. 2003;35:566-570. [PMID: 14567461 DOI: 10.1016/s1590-8658(03)00029-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
4 Tsai CE, Liang CM, Lee CH, Kuo YH, Wu KL, Chiu YC, Tai WC, Chuah SK. First-line Helicobacter pylori eradication among patients with chronic liver diseases in Taiwan. Kaohsiung J Med Sci 2016;32:397-402. [PMID: 27523452 DOI: 10.1016/j.kjms.2016.05.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]